The Effect and Safety of Hydrogen Inhalation on Outcome Following Brain Ischemia During Post Cardiac Arrest Care: HYBRID study (Pilot study)

The Effect and Safety of Hydrogen Inhalation on Outcome Following Brain Ischemia During Post Cardiac Arrest Care: HYBRID study (Pilot study) - The Effect and Safety of H2 inhalation for patient with post cardiac arrest syndrome

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012381

Enrollment

Registered

2013-11-22

Start date

2013-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post cardiac arrest syndrome

Interventions

Mixed gas of oxygen and 2% hydrogen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. An age of 20 to 80 years. 2. Achieved return of spontaneous circulation. 3. Glasgow come scale >= 8. 4. Possible to receive inhalation of gas within 12 hours after return of spontaneous circulation. 5. Patient without neurological impairment before cardiac arrest event. (CPC 1 or 2) 6. SpO2 >= 94% under 50% O2 condition 7. Systolic blood pressure (SBP) >= 90 mmHg.

Exclusion criteria

Exclusion criteria: 1. Known trauma (except for suffocation), acute aortic dissection, terminal of cancer 2. Do not attempt resuscitation 3. Pregnancy 4. Usage of cardio pulmonary bypass 5. Patients judged as being inappropriate for the study by investigators

Design outcomes

Primary

Measure	Time frame
Frequency of adverse events including death and abnormal findings for 7 days after hospital admission	—

Secondary

Measure	Time frame
1.Plasma/Urine oxidative stress, Plasma cytokine, Blood hydrogen concentration 2.Survival rate at 7days, 30 days and 90 days 3.Rate of good neurological outcome (CPC 1 or 2) at 30 days and 90days	—

Countries

Japan

Contacts

Public ContactTomoyoshi Tamura

School of Medicine, Keio university Emergency and Critical care medicine

tomoyoshitamura@keio.jp03-3225-1323

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026